Skip to main content
. 2021 Apr 21;75(10):1001–1009. doi: 10.1136/jech-2020-216219

Table 4.

Abstinence rates observed, unadjusted, age-adjusted and sex-adjusted and multivariable-adjusted ORs according to randomised assignment group (intention-to-treat analysis)

Control Intervention Unadjusted Age adjusted and sex adjusted Multivariable adjusted
(n=285) (n=286) OR (95% CI); p value OR (95% CI); p value OR (95% CI); p value
Point abstinence*
 At 30 days 17 (5.96) 30 (10.49) 1.85 (1.03 to 3.46); 0.049 1.88 (1.01 to 3.50); 0.046 1.66 (0.82 to3.36); 0.157
 At 6 months 40 (14.04) 42 (14.69) 1.05 (0.66 to 1.68); 0.825 1.01 (0.63 to 1.64); 0.957 1.00 (0.49 to 1.46); 0.760
 At 12 months 34 (11.93) 57 (19.93) 1.84 (1.16 to 2.91); 0.008 1.88 (1.18 to 2.98); 0.008 1.79 (1.06 to 3.03); 0.031
Prolonged abstinence
 For 6 months† 22 (7.72) 38 (13.29) 1.83 (1.05 to 3.18); 0.037 1.86 (1.07 to 3.23); 0.028 1.80 (0.99 to 3.26); 0.054
 For 12 months‡ 6 (2.11) 16 (5.59) 2.75 (1.06 to 7.15); 0.032 2.76 (1.07 to 7.18); 0.037 2.71 (1.04 to 7.29); 0.044

Data are presented as number of patients (%), OR, CI and p value.

Analyses were unadjusted, sex adjusted and age adjusted (continuous years), and adjusted by multiple variables: sex, age, civil status, social class, number of children, primary healthcare professional performing the intervention, primary healthcare setting, cardiovascular disease, body mass index, physical activity, alcohol intake categorisation, smoking cumulative consumption, nicotine dependence level (Fagerström test), motivation to quit smoking level (Richmond test), Prochaska and DiClemente model stage, baseline expired-CO values, accept a specific ‘quit smoking’ medical visit, intensive-motivational intervention and/or use of pharmacological treatment.

*This secondary end point was self-reported 7 days point-prevalence tobacco abstinence, confirmed by expired-CO level (<10 ppm).

†This secondary end point was self-reported prolonged abstinence during the 6 months prior to the end of the follow-up period, confirmed by expired-CO level (<10 ppm) at 30 days, 6 and 12 months.

‡This primary end point was self-reported prolonged abstinence during the 12 months prior to the end of the follow-up period, confirmed by expired-CO level (<10 ppm) at 6 and 12 months.